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In basic and applied myology, gel-based proteomics is routinely used for studying global changes in the
protein constellation of contractile fibers during myogenesis, physiological adaptations, neuromuscular
degeneration, and the natural aging process. Since the main proteins of the actomyosin apparatus and
its auxiliary sarcomeric components often negate weak signals from minor muscle proteins during pro-
teomic investigations, we have here evaluated whether a simple prefractionation step can be employed
to eliminate certain aspects of this analytical obstacle. To remove a large portion of highly abundant con-
tractile proteins from skeletal muscle homogenates without the usage of major manipulative steps, dif-
ferential centrifugation was used to decisively reduce the sample complexity of crude muscle tissue
extracts. The resulting protein fraction was separated by two-dimensional gel electrophoresis, and 2D-
landmark proteins were identified by mass spectrometry. To evaluate the suitability of the contractile-
protein-depleted fraction for comparative proteomics, normal versus dystrophic muscle preparations
were examined. The mass spectrometric analysis of differentially expressed proteins, as determined by
fluorescence difference in-gel electrophoresis, identified 10 protein species in dystrophic mdx hindlimb
muscles. Interesting new biomarker candidates included Hsp70, transferrin, and ferritin, whereby their
altered concentration levels in dystrophin-deficient muscle were confirmed by immunoblotting.
 2013 Elsevier Inc. All rights reserved.In high-throughput biochemistry, mass spectrometry is the
method of choice for the fast and reliable identification of proteins
in large-scale surveys of physiological or pathological processes
[1–3]. This makes protein mass spectrometry an integral part of
biological network analysis [4] and the discovery of novel disease
biomarker signatures [5]. Disorder-specific protein markers play
a central diagnostic, prognostic, and therapeutic role in skeletal
muscle pathology and the systematic application of proteomics
has greatly expanded the range of biomarkers for neuromuscular
disorders [6]. Proteome-wide studies combine protein separation
methods, such as high-resolution two-dimensional gel electropho-
resis [7–9] and liquid chromatography [10], with sophisticated
mass spectrometric techniques to determine potential changes in
protein concentration, isoform expression patterns, protein–pro-
tein interactions and posttranslational modifications [11–13].
However, proteomic findings from comparative studies focus-
ing on total protein extracts from highly complex and dynamic
types of tissues, such as skeletal muscle fibers, are often limited
to mostly soluble and relatively abundant proteins [14–16], miss-
ing especially the classes of very low abundance proteins andhydrophobic proteins. Thus, to cover all of the assessable constitu-
ents in a heterogeneous assembly of proteins with a greatly differ-
ing abundance and physicochemical properties, as are found in
contractile tissues, organelle proteomics should be used to supple-
ment the findings from whole tissue proteomics. The application of
prefractionation procedures substantially reduces sample com-
plexity and thus allows more comprehensive cataloging of com-
plex muscle protein mixtures [17–20]. Muscle organelle
proteomics has been successfully applied for studying fractions en-
riched in nuclei, mitochondria, surface membranes, the sarcoplas-
mic reticulum, the cytosol, and the contractile apparatus in normal,
transforming, and pathological muscle [21].
Although the comprehensive analysis of low-copy number pro-
teins in pathological samples is challenging, the proteomic identi-
fication of new protein disease markers promises a deeper
understanding of pathophysiological mechanisms. To better com-
prehend the complex changes that occur during X-linked muscular
dystrophy [22], we have analyzed here a contractile-protein-de-
pleted fraction from normal versus dystrophic muscle prepara-
tions. Since extensive subcellular fractionation protocols may
introduce artifacts, we have kept centrifugation steps to a mini-
mum. Hence, the analytical strategy employed in this study is a
compromise between using total extracts, which may result in
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prefractionation protocols, which often complicate comparative
studies by unintended entrapment, desorption, or clustering of
certain proteins. Our study complements previous proteomic
investigations into global changes in genetic animal models of
Duchenne muscular dystrophy [23–27]. The proteomic analysis
of the enriched protein fraction from normal versus dystrophic
mdx muscle has resulted in the identification of 10 novel protein
species, including ferritin, transferrin, and various isoforms of the
molecular chaperone Hsp70.Materials and methods
Materials
For the gel electrophoretic separation of muscle proteins, mate-
rials and analytical grade chemicals, including CyDye DIGE fluor
minimal dyes Cy3 and Cy5, were obtained from Amersham Biosci-
ences/GE Healthcare (Little Chalfont, Buckinghamshire, UK). Diges-
tion was performed with sequencing-grade-modified trypsin from
Promega (Madison, WI, USA). Protease inhibitors and chemilumi-
nescence substrate were purchased from Roche Diagnostics
(Mannheim, Germany). Primary antibodies were from Abcam
(Cambridge, UK; ab92721 to myosin light chain MLC2, ab6588 to
collagen, ab11427 to parvalbumin, ab9033-1 to transferrin, and
ab69090 to ferritin light chain), Sigma Chemical Co. (Dorset, UK;
L-9393 to laminin), Enzo Stressgen (Victoria, BC, Canada; ADI-
SPA-811 to heat shock protein Hsp70/72 rabbit), and Santa Cruz
Biotechnology (Santa Cruz, CA, USA; sc-3370 to b-dystroglycan).
Secondary antibodies were from Chemicon International (Temecu-
la, CA, USA). All other chemicals used were of analytical grade and
purchased from Sigma.
Animal model of muscular dystrophy
Dystrophin-deficient skeletal muscles from the naturally occur-
ring mutant mdx mouse model of Duchenne muscular dystrophy
are widely used in proteomic screening studies [23]. Since this
study employed a subcellular fractionation protocol prior to gel
electrophoretic separation of the contractile-protein-depleted frac-
tion and therefore required substantial amounts of starting mate-
rial, the proteomic analysis was not carried out with a specific
skeletal muscle, but combined muscles from the entire hindlimb.
Dystrophic muscle from 8-week-old mdx mice and normal control
muscle from age-matched C57 mice were obtained from the Biore-
source Unit of the University of Bonn [26]. Mice were kept under
standard conditions and all procedures were performed in accor-
dance with German guidelines on the use of animals for scientific
experiments. Animals were sacrificed by cervical dislocation and
muscle tissues quickly removed and quick-frozen in liquid
nitrogen.
Subcellular fractionation of skeletal muscle homogenates
The subcellular fractionation of skeletal muscle tissue was
based on previously optimized protocols for the separation of dis-
tinct functional elements from muscle homogenates [28,29]. Each
pair of hindlimb muscles of approximately 0.65 g wet wt from
mdx and control mice was washed in ice-cold phosphate-buffered
saline and cut into small pieces with a razor blade. Following sus-
pension in 10 vol of 20 mM sodium pyrophosphate, 20 mM sodium
phosphate, 1 mM MgCl2, 0.303 M sucrose, 0.5 mM EDTA, pH 7.0
[28], supplemented with a protease inhibitor cocktail [29], samples
were treated with a hand-held homogenizer for 30 s every 10 min
for 1 h at 4 C. Muscle homogenates were centrifuged at 14,000gfor 15 min and then the resulting supernatant was pelleted at
100,000g for 1 h at 4 C. Microsomal pellets were resuspended in
electrophoresis buffer and analyzed by gel-based proteomics.
One preparation yielded approximately 0.8 mg of microsomal
protein.
Gel electrophoretic analysis of muscle proteins
Fluorescence two-dimensional (2D) gel electrophoretic analysis
was carried out in the case of total tissue extracts by postelec-
trophoretic staining with ruthenium II tris bathophenanthroline
disulfonate (RuBPs) [30] and for the comparative analysis of the
contractile-protein-depleted fraction from normal versus dystro-
phic muscle by preelectrophoretic labeling using the difference
in-gel electrophoresis (DIGE) method with CyDyes Cy3 and Cy5
[31]. Fluorescent RuBPs dye was prepared by the method of
Aude-Garcia et al. [32]. First-dimension isoelectric focusing was
performed with nonlinear pH 3–11 strips and second-dimension
slab-gel electrophoresis with 12.5% separating gels (gel size
24  16 cm). Our laboratory has optimized fluorescence labeling
techniques for the analysis of skeletal muscle proteins. Detailed
descriptions of the RuBPs-based analysis and the DIGE method as
applied to muscle tissues have recently been published [33,34]. To-
tal protein loading of RuBPs gels and DIGE gels was 600 and 100 lg
protein, respectively. Fluorescently labeled proteins were visual-
ized with the help of a Typhoon Trio variable mode imager (Amer-
sham Biosciences/GE Healthcare). Gel image analysis was carried
out with Progenesis SameSpots software (Nonlinear Dynamics,
Newcastle upon Tyne, UK). The following parameters were em-
ployed for the identification of significant differences in the con-
centration of proteins in the contractile-protein-depleted fraction
from normal versus dystrophic muscle: ANOVA p < 0.05, n = 4,
and a power value of >0.8. Proteins in 2D spots with a significant
increase or decrease in abundance (differing between the various
groups with >1.4-fold change) were subsequently identified by
mass spectrometry.
Mass spectrometric identification of muscle proteins
Coomassie brilliant blue (CBB)-stained pick gels were used for
the mass spectrometric identification of proteins of interest, as pre-
viously described in detail [35]. Total protein loading of CBB pick
gels was 600 lg protein. Following the excision, washing, and
destaining of 2D spots, characteristic peptide populations were
produced by treatment with sequencing-grade trypsin [31]. Pep-
tide samples were dried through vacuum centrifugation and sus-
pended in MS-grade distilled water and 0.1% formic acid, spun
down through spin filters, and added to LC–MS vials for identifica-
tion using a Model 6340 ion trap LC–MS apparatus from Agilent
Technologies (Santa Clara, CA, USA). Conditions for the separation
of peptide populations generated from individual muscle proteins
and elution profiles were previously described in detail
[30,31,33–35]. Database searches were carried out with Mascot
MS/MS ion search (Matrix Science, London, UK; NCBI database, re-
lease 20100212). All searches employed ‘‘Mus musculus’’ as taxo-
nomic category and the following parameters: (i) two missed
cleavages by trypsin, (ii) mass tolerance of precursor ions ±2 Da
and product ions ±1 Da, (iii) carboxymethylated cysteines fixed
modification, (iv) oxidation of methionine as variable modification,
and (v) at least two matched distinct peptides. MS/MS scores over
40 are listed in Tables 1–3.
Immunoblot analysis of muscle proteins
One-dimensional gel electrophoretic separation and immuno-
blotting were carried out by standard procedures [36] and used
A B
C
Fig. 1. Differential centrifugation approach to produce a contractile-protein-depleted fraction for comparative subproteomic studies. (A) Shown is a flow chart outlining the
subcellular fractionation steps used to swiftly isolate a fraction representing low-copy-number proteins present in normal versus dystrophic skeletal muscle homogenates.
The successful separation of the plentiful contractile protein fraction from a pellet with less abundant muscle proteins is visualized by the considerably different protein spot
patterns in (B) the fluorescent two-dimensional gel images of crude tissue extracts versus (C) the protein pellet following ultracentrifugation. An open circle highlights the
contractile protein-containing region of 2D gels in the acidic-to-neutral pI range.
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of the contractile-protein-depleted fraction from normal versus
dystrophic muscle. Using a Mini-Protean II electrophoresis and
transfer system from Bio-Rad Laboratories (Hercules, CA, USA),
muscle proteins were transferred to nitrocellulose for 70 min at
100 V and 4 C. A fat-free milk protein solution made up inFig. 2. Two-dimensional gel electrophoretic analysis of total mouse skeletal muscle extra
total tissue extracts. MS identification was successfully applied to a large number of 2D-
circles and are numbered 1 to 30. The pH values of the first-dimension gel system and the
and on the left, respectively.phosphate-buffered saline was used to block membranes for 1 h
[29]. Membrane sheets were then incubated with sufficiently di-
luted primary antibodies for 3 h, washed several times, incubated
for 1 h with secondary peroxidase-conjugated antibodies, and
washed again, and then immuno-decorated bands were visualized
with the chemiluminescence method. Densitometric scanning ofcts. Shown is a RuBPs-labeled 2D gel representing major protein species from crude
landmark proteins from total muscle extracts (see Table 1). Proteins are marked by
molecular mass standards (in kDa) of the second dimension are indicated on the top
Comparative proteomic analysis of the contractile-protein-depleted / S. Carberry et al. / Anal. Biochem. 446 (2014) 108–115 111immunoblots was performed using ImageJ (National Institutes of
Health, Bethesda, MD, USA) software.Results
Differential centrifugation of muscle homogenates
As outlined in Fig. 1, this study evaluated the suitability of a
simple subcellular fractionation protocol for the swift removal of
a large portion of the actomyosin apparatus from muscle homoge-
nates to enable the comparative analysis of low-copy-number
proteins by gel-based subproteomics. The separation of the plenti-
ful contractile protein fraction from a microsomal pellet represent-
ing less abundant muscle proteins, as diagrammatically shown in
the flow chart of Fig. 1A, is substantiated by the clearly different
protein expression patterns in the fluorescent two-dimensional
gel images. The drastic decrease in protein spots in the acidic-to-
neutral region on the left side of the gel image in Fig. 1C, compared
to the crude extract depicted in Fig. 1B, indicates the successful re-
moval of a considerable part of contractile elements, such as myo-
sins, actins, troponins, and tropomyosins [16,29]. To verify the
depletion of the actomyosin apparatus, mass spectrometry was
employed to unequivocally identify abundant landmark protein
spots within two-dimensional gels before and after differential
centrifugation.Gel electrophoretic assessment of the contractile-protein-depleted
fraction
Following the gel electrophoretic separation and densitometric
analysis of proteins present in crude muscle extracts (Fig. 2) and
the contractile-protein-depleted subcellular fraction (Fig. 3), the
mass spectrometric identification of 2D-landmark protein spots
was carried out, and findings are listed in Tables 1 and 2. The tables
list the names of identified proteins and their accession number,
MS/MS score, isoelectric point, molecular mass, number of pep-
tides, and percentage sequence coverage. A substantial number
of the 2D-landmark proteins marked in Fig. 2 (spots 4, 11, 19,
22–29) belong to the class of contractile proteins. Table 1 lists theirFig. 3. Two-dimensional gel electrophoretic analysis of the contractile-protein-depleted
species from the contractile-protein-depleted fraction. Compared to the gel image sho
contractile-protein-containing spots. MS identification was successfully applied to a la
Proteins are marked by circles and are numbered 1 to 39. The pH values of the first-dimen
are indicated on the top and on the left, respectively.identity as myosin light chains MLC1f (spots 19 and 29) and MLC2
(spots 26–28), actin (spot 4), tropomyosin (spot 11), troponin TnI
(spot 22), and troponin TnT (spots 23–25). In contrast, many of
the more neutral-to-acidic protein species belonging to this class
of muscle proteins have apparently been removed by differential
centrifugation. The list of protein spots marked in Fig. 3 of the sub-
cellular fraction contains only a small number of minor spots with
contractile elements, such as actin (spots 16 and 17) and tropomy-
osin (spots 20 and 21) (Table 2). The high concentration of proteins
in the pH 8 range is possibly due to the increased concentration of
hydrophobic proteins in the subcellular fraction. Various basic
integral proteins poorly label and exhibit an impaired electropho-
retic mobility, which might explain the streaky pattern in the pH 9
region of 2D-DIGE gels. For example, our MS-based screening of
proteins in the subcellular fraction revealed the presence of the
small integral membrane protein 11 (Accession Nos.
GI:20270271, NP_620082, MS/MS score 48) at pI 10.01. We have
not added this proteomic hit in Table 2, since this protein was
identified by only one peptide. Many of the other 2D-landmark
proteins in both gels with crude extracts and the subcellular frac-
tion from skeletal muscle homogenates were identified as compo-
nents that belong to the class of metabolic enzymes, ion handling
proteins, and molecular chaperones.Comparative proteomic analysis of normal versus dystrophic proteins
The comparative proteomic investigation of normal versus dys-
trophic mdx muscle, carried out with the contractile-protein-de-
pleted fraction, revealed differential expression patterns for 10
distinct protein spots. A DIGE master gel with the marked proteins
that exhibited concentration changes in dystrophin-deficient mus-
cle is presented in Fig. 4. Table 3 lists their mass spectrometric
identification. Changed proteins were found to be isoforms of the
molecular chaperone Hsp70 (spots 1–3, 6), an unnamed protein
BAC34145 (spots 4, 5), ferritin light chain (spot 7), transferrin (spot
8), peptidylprolyl cis–trans isomerase (spot 9), and phosphogluco-
mutase (spot 10). While the two enzymes were shown to be re-
duced in abundance, the heat shock proteins and iron-binding
proteins were demonstrated to be increased in density (Table 3).fraction from mouse skeletal muscle. Shown is a 2D gel representing major protein
wn in Fig. 2, the 2D gel region in the acidic-to-neutral pI range is void of major
rge number of 2D-landmark proteins from this subcellular fraction (see Table 2).
sion gel system and the molecular mass standards (in kDa) of the second dimension
Table 1
List of MS-identified 2D-landmark proteins in the crude tissue extract from skeletal muscle.
Spot Protein name Accession
No.
MS/MS
score
Isoelectric point
(pI)
Molecular mass
(Da)
No. of peptides Coverage
(%)
1 ATP synthase, Atp5b protein AAH37127 834 5.24 56,632 34 67
2 Enolase, b NP_031959 1249 6.73 47,343 27 63
3 Enolase, b NP_031959 693 6.73 47,343 28 61
4 Actin, b CAA27396 481 5.78 39,451 15 27
5 Creatine kinase, M-type NP_031736 911 6.58 43,250 20 44
6 Creatine kinase, M-type NP_031736 949 6.58 43,250 21 46
7 Fructose-bisphosphate aldolase A isoform 2 NP_031464 344 8.31 39,795 21 57
8 Fructose-bisphosphate aldolase A isoform 2 NP_031464 1063 8.31 39,795 22 66
9 Calsequestrin, skeletal muscle AAC63616 219 3.93 45,619 12 28
10 Calsequestrin, skeletal muscle AAC63616 463 3.93 45,619 9 25
11 Tropomyosin, b chain isoform 1 NP_033442 232 4.66 32,933 12 30
12 Malate dehydrogenase, mitochondrial NP_032643 301 8.93 36,053 11 44
13 Creatine kinase, M-type NP_031736 551 6.58 43,250 15 34
14 Glyceraldehyde-3-phosphate dehydrogenase AAH85315 281 7.59 36,099 12 46
15 Creatine kinase, M-type NP_031736 879 6.58 43,250 19 43
16 Myozenin-1 NP_067483 406 8.57 31,438 13 62
17 Carbonic anhydrase, CA3 isoform NP_031632 167 6.89 29,638 15 58
18 Creatine kinase, M-type NP_031736 267 6.58 43,250 13 23
19 Myosin light chain MLC1/3 muscle isoform 1f NP_067260 792 4.98 20,697 17 78
20 Adenylate kinase isoenzyme AK1 NP_067490 497 5.7 23,334 20 74
21 Triosephosphate isomerase AAB48543 323 5.62 22,724 12 83
22 Troponin TnI, fast skeletal muscle NP_033431 191 8.65 21,518 12 31
23 Troponin TnT, fast muscle isoform AAB39743 237 9.01 29,358 6 13
24 Troponin TnT, fast muscle isoform AAL77612 351 5.08 36,537 8 14
25 Troponin TnT, fast muscle isoform AAB39743 378 9.01 29,358 10 18
26 Myosin light chain MLC2, skeletal muscle
isoform
NP_058034 883 4.82 19,059 22 92
27 Myosin light chain MLC2, skeletal muscle
isoform
NP_058034 463 4.82 19,059 21 92
28 Myosin light chain MLC2, skeletal muscle
isoform
NP_058034 162 4.82 19,059 7 52
29 Myosin light chain MLC1/3, muscle isoform 1f NP_067260 313 4.98 20,697 11 39
30 Parvalbumin, a NP_038673 659 5.02 11,923 12 71
Comparative proteomic analysis of the contractile-protein-depleted / S. Carberry et al. / Anal. Biochem. 446 (2014) 108–115 112During an aging study of the dystrophic diaphragm, as previously
published for the 8-week to 22-month range [26], we also investi-
gated the 8-week to 12-month range and found a significant in-
crease in heat shock protein Hsp70 cognate (Accession No.
AAA37869; MS/MS score 167; pI 5.37; molecular mass 71,025; 5
peptides; 11% coverage; 3.4-fold increase in mdx muscle) and fer-
ritin light chain (Accession No. NP_034370; MS/MS score 145; pI
5.66; molecular mass 20,817; 10 peptides; 65% coverage; 5.4-fold
increase in mdx muscle).
Comparative immunoblotting of normal versus dystrophic muscle
Immunoblot analysis was employed to verify the concentration
changes in transferrin, Hsp70, and ferritin in normal versus mdx
preparations (Fig. 5). Prior to evaluating novel candidates with an
altered expression in mdx hindlimb muscle, established marker
proteins with no changed abundance, increased abundance, or de-
creased abundance were blotted. Immunoblots in Fig. 5A–F were
carried out with crude tissue extracts to demonstrate altered
expression levels on the global muscle protein level. However,
immunolabeling of ferritin did not result in a strong enough signal.
Therefore this analysis, in combination with the unaltered marker
protein parvalbumin, was performed with the contractile-protein-
depleted fraction (Fig. 5G and H). Immuno-decoration of myosin
light chain MLC2, laminin, and parvalbumin showed comparable
levels in normal versusmdx preparations (Fig. 5A, B, and G). In con-
trast, the dystrophin-associated glycoprotein b-dystroglycan
(Fig. 5C) and the extracellular matrix protein collagen (Fig. 5D) dis-
played drastically altered expression levels in dystrophin-deficient
muscle. This agrees with the established reduction of b-dystrogly-
can in dystrophinopathy [37] and the considerable increase in
collagen inmdx samples [26], as well as an unaltered concentrationof various proteins in dystrophic leg muscles [35]. Immunoblotting
of the newly established marker candidates of X-linked muscular
dystrophy, as identified here by subcellular proteomics, clearly
verified their altered concentration in dystrophic muscle. Transfer-
rin, Hsp70, and ferritin light chain exhibited statistically significant
increases in mdx hindlimb muscle (Fig. 5E, F, and H).Discussion
Subproteomic studies have clearly shown that organelle proteo-
mics is highly suitable for the evaluation of global changes in dis-
tinct subcellular fractions from skeletal muscles during
physiological adaptations or pathological alterations [21].
Although the primary abnormalities causing X-linked muscular
dystrophy have been thoroughly established and the correspond-
ing deficiency in the membrane cytoskeletal protein dystrophin
is well documented, little is known about the complexity of sec-
ondary changes leading to dystrophinopathy. Previous proteomic
studies have mostly focused on total tissue extracts and therefore
identified mainly abundant muscle-associated proteins, such as
components involved in metabolism, excitation–contraction cou-
pling, ion handling, the cellular stress response, and stabilization
of the cytoskeleton and extracellular matrix [23–27,30,35]. In con-
trast, the depletion of the contractile apparatus by differential cen-
trifugation, as shown in this report, enables the comparative
proteomic screening of minor protein species in normal versus
dystrophic preparations. Minor muscle-associated proteins with a
changed concentration in mdx muscle were identified as various
isoforms of heat shock protein Hsp70, ferritin light chain, transfer-
rin, and the enzymes peptidylprolyl cis–trans isomerase and
phosphoglucomutase.
Table 2
List of MS-identified 2D-landmark proteins in the contractile protein-depleted fraction from skeletal muscle.
Spot Protein name Accession No. MS/MS
score
Isoelectric point
(pI)
Molecular mass
(Da)
No. of
peptides
Coverage
(%)
1 Transferrin AAL34533 41 6.92 78,832 4 6
2 Phosphofructokinase, muscle GI:13529638 53 8.24 86,119 8 10
3 Heat shock protein Hsp70, inducible ABK96811 136 5.53 70,378 5 11
4 Heat shock protein Hsp70, mitochondrial BAA04493 82 5.91 73,773 4 7
5 Heat shock protein Hsp70, mortalin AAB28641 99 5.72 73,403 4 6
6 Heat shock protein Hsp70, mitochondrial BAA04493 74 5.91 73,773 2 3
7 Pgm2 protein, partial GI:33416468 109 6.02 63,700 12 24
8 Pyruvate kinase, muscle isoform M1 GI:359807367 182 6.69 58,470 11 22
9 Pyruvate kinase, muscle isoform M1 GI:359807367 148 6.69 58,470 9 22
10 ATP synthase Atp5b protein GI:23272966 42 5.24 56,632 5 12
11 Hippocalcin-like protein 1 GI:407263738 44 5.54 22,459 2 28
12 Enolase, b GI:6679651 110 6.73 47,343 4 14
13 Enolase, b GI:6679651 107 6.73 47,343 4 13
14 Enolase, b GI:6679651 316 6.73 47,343 15 45
15 Enolase, b GI:6679651 241 6.73 47,343 12 35
16 Actin, a, skeletal muscle GI:4501881 62 5.23 42,372 7 19
17 b-Actin-like protein 2 GI:30425250 44 5.3 42,325 2 4
18 Creatine kinase, M-type GI:6671762 181 6.58 43,250 6 22
19 Fructose-bisphosphate aldolase A isoform 2 GI:6671539 71 8.31 39,795 10 30
20 Tropomyosin, b chain GI:11875203 42 4.66 32,933 2 9
21 Tropomyosin, a-1 chain isoform 3 GI:31560030 92 4.71 32,747 9 17
22 Enolase, b GI:6679651 138 6.73 47,343 5 16
23 Glyceraldehyde-3-phosphate dehydrogenase GI:6679937 83 8.44 36,077 6 20
24 Malate dehydrogenase, cytosolic GI:387129 108 6.16 36,628 4 16
25 Malate dehydrogenase, cytosolic GI:387129 113 6.16 36,628 4 16
26 Phosphoglycerate mutase 2 GI:9256624 93 8.65 28,980 7 22
27 Triosephosphate isomerase GI:54855 116 6.9 27,021 4 20
28 Triosephosphate isomerase GI:54855 125 6.9 27,021 8 55
29 Phosphoglycerate mutase 2 GI:9256624 60 8.65 28,980 4 17
30 DJ-1 protein GI:55741460 42 6.32 20,236 3 12
31 Thioredoxin-dependent peroxide reductase,
mitochondrial
GI:6680690 57 7.15 28,337 4 16
32 Manganese superoxide dismutase GI:53450 36 8.8 24,894 2 3
33 Phosphatidylethanolamine binding protein GI:1517864 93 5.19 21,018 3 18
34 Adenylate kinase, isoenzyme AK1 GI:10946936 87 5.7 23,330 5 33
35 Ferritin light chain 1 GI:120524 81 5.66 20,847 4 32
36 Peptidylprolyl cis–trans isomerase A NP_032933 89 7.74 18,134 4 35
37 Parvalbumin GI:53819 80 5.02 11,937 3 26
38 Parvalbumin GI:53819 136 5.02 11,937 6 57
39 Hemoglobin b GI:229301 98 7.26 15,767 5 40
Fig. 4. DIGE master gel of subcellular fraction showing significant changes in dystrophic mdx leg muscle. Shown is the fluorescent gel image of the analysis of dystrophin-
deficient leg muscle from the mdx mouse model of Duchenne muscular dystrophy. Muscle proteins with a changed abundance are marked by circles and numbered 1 to 10.
See Table 3 for the mass spectrometric identification of altered muscle proteins in muscular dystrophy. The pH values of the first-dimension gel system and the molecular
mass standards (in kDa) of the second dimension are indicated on the top and on the left, respectively.
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Table 3
Changed proteins in subcellular fraction from mdx leg muscle as determined by fluorescent 2D-DIGE analysis.
Spot Protein name Accession
No.
MS/MS
score
Isoelectric point
(pI)
Molecular mass
(Da)
No. of
peptides
Coverage
(%)
Fold
change
1 Heat shock protein Hsp70,
mitochondrial
BAA04493 74 5.91 73,773 2 3 1.9
2 Heat shock protein Hsp70, mortalin AAB28641 99 5.72 73,403 4 6 1.9
3 Heat shock protein Hsp70,
mitochondrial
BAA04493 82 5.91 73,773 4 7 1.9
4 Unnamed protein product BAC34145 238 5.75 70,730 11 22 1.8
5 Unnamed protein product BAC34145 305 5.75 70,730 9 18 1.8
6 Heat shock protein Hsp70, inducible ABK96811 136 5.53 70,378 5 11 1.7
7 Ferritin light chain 1 GI:120524 81 5.66 20,847 4 32 1.6
8 Transferrin AAL34533 41 6.92 78,832 4 6 1.6
9 Peptidylprolyl cis–trans isomerase A NP_032933 89 7.74 18,134 4 35 1.4
10 Pgm2 protein, partial GI:33416468 109 6.02 63,700 12 24 1.7
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Fig. 5. Immunoblot analysis of normal versus mdx skeletal muscle. Shown are representative immunoblots with expanded views of immuno-decorated bands.
Immunoblotting was carried out with antibodies to (A) myosin light chain MLC2, (B) laminin, (C) b-dystroglycan, (D) collagen, (E) transferrin, (F) Hsp70, (G) parvalbumin, and
(H) ferritin light chain. Lanes 1 and 2 and lanes 3 and 4 represent normal versus dystrophic muscle preparations from total tissue extracts and the contractile-protein-
depleted subcellular fraction, respectively. Underneath individual immunoblots are shown graphical presentations of the statistical evaluation of immuno-decoration. The
comparative blotting between normal and mdx muscle was statistically evaluated using an unpaired Student’s t test (n = 4; ⁄p < 0.05, ⁄⁄p < 0.005, ⁄⁄⁄p < 0.001). The
concentrations of b-dystroglycan, collagen, transferrin, Hsp70, and ferritin light chain were significantly different between normal and dystrophic mdx leg muscle.
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proteins and crucial elements of iron metabolism [40]. Increased
levels of transferrin and ferritin in dystrophic muscle agree with
recent findings from the proteomic analysis of the aged mdx dia-
phragm [26] and the aged mdx heart [41]. Deficiency in dystrophin
appears to disturb iron homeostasis, and the increased concentra-
tion of iron-binding-proteins and transporters might reflect a com-
pensatory mechanism to prevent a harmful iron overload in
muscle tissues. Increased levels of molecular chaperones are indic-
ative of enhanced cellular stress in dystrophic muscle tissue. Heat
shock protein Hsp70 is a major molecular chaperone and exists asseveral different isoforms [42]. Hsp70 isoforms play major roles in
skeletal muscle stress triggered by injury, excessive exercise,
reperfusion-induced ischemia, oxidative conditions, and neuro-
muscular disorders [43]. Chaperone regulation was shown to be
crucial for protecting stressed muscle from damage [44]. Thus,
the apparent upregulation of mitochondrial Hsp70 isoforms can
be interpreted as a countermeasure to protect dystrophic fibers
from excessive oxidative stress and agrees with previous findings
on increased levels of the small heat shock protein cvHsp in dystro-
phin-deficient skeletal muscle [45]. In addition to Hsp70, two pro-
tein spots with similar molecular masses and slightly different
Comparative proteomic analysis of the contractile-protein-depleted / S. Carberry et al. / Anal. Biochem. 446 (2014) 108–115 115isoelectric points showed an increased concentration. These pro-
tein spots correspond to an unnamed protein (BAC34145 protein,
GI:26340966) with unknown function.
The reduction in the enzymes peptidylprolyl isomerase and
phosphoglucomutase indicates impaired protein-folding processes
and abnormal glycogen utilization in mdx muscle, respectively.
Peptidylprolyl isomerase facilitates the accelerated folding of pro-
teins. In oligopeptides, this enzyme catalyzes the cis–trans isomer-
ization of proline imidic peptide bonds [46]. Thus, its reduced
presence might lower the ability of dystrophic muscles to properly
refold certain classes of muscle proteins. Phosphoglucomutase
mediates the interconversion of glucose 1-phosphate and glucose
6-phosphate during glycogenolysis and glycogenesis, making it a
critical protein of glycogen and glucose metabolism in muscle
[47]. Decreased levels of this enzyme point toward impaired glu-
cose utilization in dystrophic muscle fibers.
Hence, the systematic depletion of contractile proteins from
muscle preparations prior to gel electrophoretic protein separation
has been shown to provide better access to minor protein species
from dystrophic muscle. This report demonstrates that the applica-
tion of gel-based organelle proteomics can overcome certain tech-
nical limitations of whole-tissue proteomics by reducing sample
complexity via prefractionation steps prior to mass spectrometric
analysis. Since skeletal muscle tissues are characterized by a par-
ticularly diverse range of minor protein isoforms and a large dy-
namic range of protein expression patterns, the application of
organelle proteomics for studying adapting or pathological mus-
cles promises a more comprehensive coverage of the skeletal
muscle proteome.Acknowledgments
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